U.S., Oct. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07873931) titled 'A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases' on Oct. 08.
Brief Summary: The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), systemic sclerosis (SSc), rheumatoid arthritis (RA), and Sjogren's disease (SjD).
Study Start Date: Oct. 30
Study Type: INTERVENTIONAL
Condition:
Systemic Lupus Erythematosus
Sjogren's Disease
Rheumatoid Arthritis
Idiopathic Inflammatory Myopathies
Systemi...